Clinical Trials
27 trialsNCT07005297 2026-06-05
Clinical Genetics Branch Eligibility Screening Survey
National Institutes of Health Clinical Center (CC)
Not yet recruiting
NCT07527325 2026-06-05
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
University of California, Irvine
Phase 2 Not yet recruiting
NCT07621614 2026-06-05
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Children's Oncology Group
Phase NA Not yet recruiting
NCT07628894 2026-06-05
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07619898 2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2 Not yet recruiting
NCT07492680 2026-05-29
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT07615881 2026-05-29
IpiD
Amsterdam UMC, location VUmc
Phase 1/2 Not yet recruiting
NCT07340619 2026-05-19
EPIBREAST
UNICANCER
Phase 2 Not yet recruiting
NCT07597070 2026-05-19
UNIFIER
University of Florida
Phase 2/3 Not yet recruiting
NCT07581509 2026-05-14
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
NCT07280715 2026-05-11
IRIS
University of Pittsburgh
Phase NA Not yet recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT07574047 2026-05-07
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Swiss Cancer Institute
Phase 4 Not yet recruiting
NCT07444606 2026-05-06
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07565285 2026-05-04
INFLECTION-003
Primmune Therapeutics, Inc.
Phase 2 Not yet recruiting
NCT07556380 2026-04-29
SESAME
Northwestern University
Phase NA Not yet recruiting
NCT07552597 2026-04-27
MagMen-II
Vastra Gotaland Region
Phase 3 Not yet recruiting
NCT07389525 2026-04-24
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Indiana University
Phase EARLY_PHASE1 Not yet recruiting
NCT07518043 2026-04-15
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT07529080 2026-04-14
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
Phase NA Not yet recruiting
NCT07517653 2026-04-08
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07511036 2026-04-06
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07476326 2026-04-03
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
NCT07501104 2026-03-30
TRIUMPH-AM
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07492121 2026-03-25
GAPIMET
University of Zurich
Phase 2 Not yet recruiting
NCT06708455 2026-03-19
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Rapa Therapeutics LLC
Phase 2 Not yet recruiting
NCT07475572 2026-03-16
A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Alvotech Swiss AG
Phase 1 Not yet recruiting